Published in N Engl J Med on July 24, 2011
Phase III Acute Coronary Syndrome (APPRAISE-2) | NCT00831441
Effects of Edoxaban on Platelet Aggregation (Edoxaban) | NCT05122455
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed. Can Fam Physician (2012) 1.38
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04
Independent data monitoring committees: preparing a path for the future. Am Heart J (2014) 0.97
Anticoagulation in heart failure: current status and future direction. Heart Fail Rev (2013) 0.93
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. J Am Heart Assoc (2015) 0.92
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
Practical management of patients on apixaban: a consensus guide. Thromb J (2013) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes (2015) 0.85
Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. J Am Heart Assoc (2017) 0.85
The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J (2014) 0.85
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J (2015) 0.82
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol (2011) 0.81
Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? Eur Heart J (2015) 0.81
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
Platelet function tests: why they fail to guide personalized antithrombotic medication. J Am Heart Assoc (2015) 0.81
Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag (2014) 0.79
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy. Curr Ther Res Clin Exp (2014) 0.78
Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease. P T (2013) 0.78
Newer oral anticoagulant agents: a new era in medicine. Curr Cardiol Rev (2012) 0.78
Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Can J Hosp Pharm (2016) 0.77
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther (2014) 0.77
Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag (2015) 0.77
Apixaban and oral implications. J Clin Exp Dent (2015) 0.77
Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77
New oral anticoagulants: are coagulation units still required? Thromb J (2014) 0.77
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol (2014) 0.76
New targets for atherothrombosis. Arterioscler Thromb Vasc Biol (2014) 0.76
New oral anticoagulant agents after ACS. Eur Heart J Acute Cardiovasc Care (2012) 0.76
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. Scientifica (Cairo) (2014) 0.76
Apixaban. Hosp Pharm (2013) 0.75
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. Ochsner J (2016) 0.75
Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding. Tex Heart Inst J (2012) 0.75
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart J (2015) 0.75
Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. Ther Clin Risk Manag (2015) 0.75
Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. Am J Cardiovasc Dis (2015) 0.75
Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. PLoS One (2014) 0.75
Acute coronary syndromes: APPRAISE-2 results published. Nat Rev Cardiol (2011) 0.75
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding. Evid Based Med (2012) 0.75
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open (2016) 0.75
Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease. Cardiol Ther (2013) 0.75
ACP Journal Club. Low-dose rivaroxaban reduced mortality in patients with a recent acute coronary syndrome. Ann Intern Med (2012) 0.75
Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. Ther Clin Risk Manag (2014) 0.75
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol (2011) 0.75
Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. Clin Cardiol (2016) 0.75
The need for multicentre cardiovascular clinical trials in Asia. Nat Rev Cardiol (2013) 0.75
Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Des Devel Ther (2015) 0.75
New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo) (2012) 0.75
Dabigatran and myocardial infarction: a foggy scenario. Vasc Health Risk Manag (2014) 0.75
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiol Res (2015) 0.75
Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ Case Rep (2016) 0.75
Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev (2012) 0.75
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther (2012) 0.75
Management of atrial fibrillation in patients undergoing percutaneous coronary intervention. Transl Med UniSa (2014) 0.75
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial. Cardiovasc Ther (2014) 0.75
Apixaban after acute coronary syndrome. N Engl J Med (2011) 0.75
Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea. Ther Clin Risk Manag (2016) 0.75
Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. Fundam Clin Pharmacol (2014) 0.75
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation (2016) 0.75
Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. Thromb J (2012) 0.75
Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. Postepy Kardiol Interwencyjnej (2016) 0.75
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thromb J (2013) 0.75
Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism. Thromb Res (2012) 0.75
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug Healthc Patient Saf (2016) 0.75
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol (2016) 0.75
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Des Devel Ther (2015) 0.75
Apixaban for oral antithrombotic therapy: is a new era coming? Mol Cell Ther (2014) 0.75
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vasc Health Risk Manag (2014) 0.75
Adverse Events as End Points: The Need to Account for Both Sides of the Same Coin. J Am Heart Assoc (2017) 0.75
[Oral anticoagulation for atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2014) 0.75
Triple antithrombotic therapy for atrial fibrillation and coronary stents. Can Fam Physician (2017) 0.75
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med (2017) 0.75
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Universal definition of myocardial infarction. Circulation (2007) 11.69
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med (2003) 9.00
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08